Background
Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52-week treatment period.
Methods
We performed a retrospective analysis in a cohort of patients with PP, with or without involvement of other skin sites. Palmoplantar Psoriasis Area and Severity Index (ppPASI) was assessed at baseline and after 4, 16, 28 and 52 weeks, to evaluate the PP severity.
Results
Sixteen patients were enrolled. The rates of ppPASI90 responses constantly increased during the period of observation and were 18.7%, 62.2%, 75.0% and 81.2% at weeks 4, 16, 28 and 52, respectively. Only two patients suspended treatment because of ineffectiveness at week 16.
Conclusion
Our data from a series of 16 patients reveal that risankizumab could represent an effective and safe therapeutic choice in patients with PP.
Dermoscopic (a), LC-OCT (b) and histopathological (c) presentation of the four study lesions. Lesion 1 was located on the right superior scapula of an 82-year-old man. Lesion 2 was located on the left pectoral region of a 65-year-old man. Lesion 3 was located on the left arm of a 68-yearold woman. Lesion 4 was located on the right side of the nose of a 64-year-old woman. All lesions were equivocal for iBCC on dermoscopy. However, for all lesions, LC-OCT examination showed bright dermal formations corresponding to thickened collagen strands on histopathology (yellow stars), irregularly arranged hyporeflective linear formations corresponding to dermal vessels (green triangles), and no evidence of BCC lobules.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.